Articles tagged "Immunosuppression"

2017 American Transplant Congress
Immunosuppressive Regimen Modification Approaches in BK Nephropathy – A Comparative Study.
H. Ahmed, A. Roche-Recinos, C. Drachenberg, R. Ugarte, N. Costa, M. Mavanur, B. Thomas, A. Haririan.
Department of Medicine, University of Maryland Medical Center, Baltimore, MD
The optimal approach for IS reduction in renal transplant recipients with BKN is not well defined. A number of clinical and in vitro studies suggest…
2017 American Transplant Congress
Outcomes Following Reduction of Immunosuppression in Solid Organ Transplant Recipients with Cryptococcosis.
P. Bryant,¹ P. Pappas,¹ C. Huisingh,¹ R. Mannon,¹ J. Locke,¹ K. Wille,¹ D. Eckhoff,¹ J. Tallaj,¹ J. Baddley.^1,2
¹Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL; ²VAMC, Birmingham, AL
Background: Cryptococcosis (crypto) is the third most common fungal infection in solid organ transplant (SOT) recipients. Although reduction of immunosuppression (IS) may improve patient outcomes…
2017 American Transplant Congress
Infectious Complications Following Hepatectomy for Pediatric Hepatoblastoma.
S. Commander, M. Kueht, T.-A. Ha, A. Rana, J. Goss, S. Vasudevan.
Pediatric Surgery, Baylor College of Medicine, Houston, TX
Purpose: To examine if patients with hepatoblastoma (HB) treated with both immunosuppression and chemotherapy have different rates of infection post-operatively than those treated with chemotherapy…
2017 American Transplant Congress
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
S. Hussain, T. Taber, M. Yaqub, O. Adebiyi, D. Mishler, A. Sharfuddin.
Indiana University Health, Indianapolis
Background: Chronic Hepatitis C Virus (HCV) infection has a negative impact on graft survival. Prior treatments were poorly tolerated and had minimal cure rates. The…
2017 American Transplant Congress
Early Steroid Withdrawal and Infection in Kidney Transplant Recipients.
S. Bae, C. Durand, L. Kucirka, S. DiBrito, R. Avery, J. Garonzik Wang, D. Segev.
Johns Hopkins School of Medicine, Baltimore, MD
One third of kidney transplant (KT) recipients currently undergo early steroid withdrawal (ESW). Although ESW may slightly increase the risk of rejection in certain subgroups,…
2017 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial.
K. Unagami,¹ M. Okumi,² T. Hirai,² D. Toki,³ H. Shirakawa,⁴ T. Shimizu,² K. Omoto,⁵ M. Inui,³ H. Ishida,² K. Nitta,¹ K. Tanabe.²
¹Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan; ⁴Urology, Ohkubo Hospital, Tokyo, Japan; ⁵Transplant Surgery, Toda Chuo General Hospital, Toda, Japan
Background:Tacrolimus (TAC)-based induction therapy appears to be the standard immunosuppressive regimen for most kidney transplantation recipients (KTRs). TAC is available as a twice-daily (TAC-BID) and…
2017 American Transplant Congress
Soluble Human Leukocyte Antigen-G Levels and Prolonged Allograft Survival: A Demographic Analysis.
C. Callaway,¹ A. Ajith,² V. Portik-Dobos,² P. Best,³ C. Zayas,³ R. Kapoor,³ A. Horuzsko,² L. Mulloy.³
¹Medical College of Georgia, Augusta University, Augusta, GA; ²Georgia Cancer Center, Augusta University, Augusta, GA; ³Section of Nephrology, Department of Medicine, Augusta University, Augusta, GA
Human leukocyte antigen-G (HLA-G) is a tolerogenic protein shown to contribute to allograft survival. Dimerized, soluble HLA-G (sHLA-Gd) has been shown to significantly prolong allograft…
2017 American Transplant Congress
Liver Transplant Recipients Undergoing Non-Transplant Surgeries and Everolimus Use as Primary Immunosuppressant- Busting the Myth of Wound Infection Due to mTOR Inhibitors.
S.-C. Hsu, A. Thorat, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan
Background:Safety of everolimus(EVR)when used at an early stage after living donor liver transplantation (LDLT) was proven by many centers including ours. However, the opponents of…
2017 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation.
M. Uehara,¹ J. Azzi,¹ B. Bahmani,^1,2 J. Cheng,³ Q. Yin,³ L. Tang,³ K. Cai,³ Q. Sun,³ M. Kwon,³ Q. Xu,² G. Brandacher,⁴ R. Abdi.¹
¹Transplantation Research Center/Renal Devision, Brigham and Women's Hospital, Boston; ²Department of Biomedical Engineering, Tufts University, Boston; ³Department of Materials Science and Engineering, University of Illinois at Urbana Champaingn, IL; ⁴Plastic and Reconstructive Surgery, Johns Hopkins Medicine, Baltimore
The homing of naïve lymphocytes to the lymph node (LN) is fundamental to the priming of alloreactive T cells. LNs possess highly restricted high endothelial…
2017 American Transplant Congress
Tracking the In Vitro Phenotype and Proliferative Capacity of CD57+ CD4 T Cells.
J. Espinosa,¹ J. Lockley,¹ F. Shaw,¹ R. Osborne,¹ M. Joshi,¹ T. Woody,¹ M. Ellis,¹ B. Hollister,¹ J. Cheeseman,¹ R. Townsend,² A. Kirk.¹
¹Duke University, Durham; ²Bristol-Meyers Squibb, Princeton
CD57+PD1- CD4 T cells are primed effectors with increased expression of adhesion molecules capable of infiltrating allografts and mediating belatacept-resistant rejection (BRR). Whether CD57 is…